Similar Search Results

Preisbildung von Arzneimitteln im internationalen Vergleich

Drabinski, Thomas - 2008

Theorie der Preisbildung auf Herstellerebene -- Zusammensetzung des Patientenpreises: Weitere Preisbildungsebenen … -- Preisbildung von Arzneimitteln im internationalen Vergleich: Ordnungspolitischer Rahmen -- Internationale Preisdifferenzierung in …, Frankreich, Italien, Schweiz, Niederlande, Spanien, Großbritannien, Australien, Kanada, USA und Japan. Insbesondere werden frei …

Persistent link: https://www.econbiz.de/10014015068

Preisbildung von Arzneimitteln im internationalen Vergleich

Drabinski, Thomas; Eschweiler, Jan; Schmidt, Ulrich - 2008

Persistent link: https://www.econbiz.de/10003684395

Price caps versus reimbursement limits : pharmaceutical regulation under market integration through parallel trade

Birg, Laura - 2019 - Revised Version March 2019

In this paper, I study the effect of parallel trade (cross border resale of goods without the authorization of the manufacturer) on pharmaceutical regulation in a North-South framework with a firm's endogenous decision to export to the South. Governments in both countries may limit prices...

Persistent link: https://www.econbiz.de/10011986314

Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals

Herr, Annika; Suppliet, Moritz - In: Journal of health economics 56 (2017), pp. 19-29

Persistent link: https://www.econbiz.de/10011798902

Price regulation and relative delays in generic drug adoption

Costa-Font, Joan; McGuire, Alistair; Varol, Nebibe - In: Journal of health economics 38 (2014), pp. 1-9

Persistent link: https://www.econbiz.de/10011282079

Essays in industrial organization : switching costs in an evolving industry price structure in two-sided markets

Keating, Bryan - 2007

Persistent link: https://www.econbiz.de/10009707949

Pricing the pharmaceuticals when the ability to pay differs

Kanniainen, Vesa; Laine, Juha; Linnosmaa, Ismo - In: Journal of the Finnish Economic Association : JFEA 2 (2021) 1, pp. 25-48

A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. This paper analyses the public insurance of a patent-protected pharmaceutical product in terms of price controls and socially optimal third-degree price discrimination. First, the paper...

Persistent link: https://www.econbiz.de/10013286496

Pharmaceutical prices under regulation : tiered co-payments and reference pricing in Germany

Herr, Annika; Suppliet, Moritz - 2012

Many countries with national health care providers and health insurances regulate the market for pharmaceuticals to steer drug demand and to control expenses. For example, they introduce reference pricing or tiered co-payments to enhance drug substitution and competition. Since 2006, Germany...

Persistent link: https://www.econbiz.de/10009522774

Competitive pricing within pharmaceutical classes : evidence on ‘‘follow-on’’ drugs in Germany 1993 - 2008

Mueller, Michael T.; Frenzel, Alexander - In: The European journal of health economics : HEPAC ; … 16 (2015) 1, pp. 73-82

Persistent link: https://www.econbiz.de/10011300287

An empirical model of drug pricing and competition : a dynamic perspective

Camejo, Rodrigo Refoios; McGrath, Clare; Rutten, F. F. H. - In: International journal of economics and business research 6 (2013) 2, pp. 173-193

Persistent link: https://www.econbiz.de/10010351165

1
2
3
4
5
6
7
8
9
10
Next
Last